Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

UFS Rector takes three months sabbatical leave
2008-05-05

The Rector of the University of the Free State (UFS), Prof. Frederick Fourie, has announced that he will be taking three months sabbatical leave as from Thursday, 8 May 2008.

Prof. Fourie recently made the request for sabbatical leave to the Chairperson of the UFS Council, Judge Faan Hancke. The request was approved given the fact that Prof. Fourie has occupied a number of demanding top-management posts for almost nine years, during which time he had to manage a number of major changes at the UFS.

According to Prof. Fourie, he originally wanted to go on sabbatical leave in the second half of 2007 before the start of his second term as rector, but it was not possible at that stage.

He was last on sabbatical in 1996 before he became Dean of the Faculty of Economic and Management Sciences in 1997 and Vice-Rector: Academic Operations in 1999.

He could not take his next five-yearly leave because in the post of vice-rector he was tasked with leading the financial-turnaround strategy for the UFS from the year 2000 and had to act as rector when the previous rector, Prof. Stef Coetzee, was on sick leave. Since being inaugurated as rector in 2003, there was also no opportunity to take leave as a result of the many key projects and urgent initiatives.

The Vice-Rector: Academic Operations and vice-chairperson of the Senate, Prof. Teuns Verschoor, will be the acting rector. Management processes and decision-making will continue as normal under the leadership of the acting rector together with the Executive Committee of the Executive Management (Exco) and the Executive Management. This applies to the decision about the future of the Reitz Residence as well as the continuing implementation of the policy on diversity in student residences.

According to Judge Hancke it was important that Prof. Fourie took sabbatical leave in the light of the long period he has been at the forefront of very demanding changes. There are many challenges that still lie ahead.

During his leave Prof. Fourie will be involved with the Higher Education South Africa (HESA) investigation into diversity and racism on campuses, with research and a national conference on institutional culture, as well as the Association of Commonwealth Universities (ACU) benchmarking project and its conference in Australia at the end of August 2008.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept